prikaz prve stranice dokumenta Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta
  Download
PDF 537.1 KB
master's thesis
Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta
2023. urn:nbn:hr:152:594692
Ivandić, Vinko
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Cite this document

Ivandić, V. (2023). Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:594692

Ivandić, Vinko. "Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2023. https://urn.nsk.hr/urn:nbn:hr:152:594692

Ivandić, Vinko. "Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2023. https://urn.nsk.hr/urn:nbn:hr:152:594692

Ivandić, V. (2023). 'Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 25 April 2024, https://urn.nsk.hr/urn:nbn:hr:152:594692

Ivandić V. Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2023 [cited 2024 April 25] Available at: https://urn.nsk.hr/urn:nbn:hr:152:594692

V. Ivandić, "Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:152:594692

Please login to the repository to save this object to your list.
Metadata
TitleRazlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestranta
Title (english)Progression-free survival difference in patients with metastatic hormone-positive breast cancer treated with ribociclib and palbociclib plus aromatase inhibitors or fulvestrant
AuthorVinko Ivandić
MentorIlijan Tomaš (mentor)
Committee memberJasmina Rajc (predsjednik povjerenstva)
Committee memberŽelimir Orkić (član povjerenstva)
Committee memberIlijan Tomaš (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2023-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Medical Biochemistry
Abstract
Ciljevi istraživanja: Ispitati postoji li razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestrant Ustroj studije: presječno istraživanje Ispitanici i metode: Istraživanje je provedeno na 66 bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih na Zavodu za onkologiju Kliničkog bolničkog centra Osijek u razdoblju od rujna 2018. do 28. veljače 2023. Podatci o bolesnicama prikupljeni su obradom dostupne medicinske dokumentacije. U istraživanje su uključene bolesnice koje su u prvoj liniji liječenja metastatske bolesti liječene ribociklibom uz inhibitor aromataze ili fulvestrant te bolesnice koje su u prvoj liniji liječenja metastatske bolesti liječene palbociklibom uz inhibitor aromataze ili fulvestrant. Rezultati: U prvoj liniji liječenja metastatskog hormonski ovisnog raka dojke 35 bolesnica liječeno je ribociklibom, a 31 bolesnica liječena je palbociklibom uz inhibitore aromataze ili fulvestrant. Medijan vremena do progresije bolesti kod bolesnica liječenih ribociklibom uz inhibitor aromataze ili fulvestrant iznosi 11 mjeseci (95 % raspon pouzdanosti 6 – 15), a kod bolesnica liječenih palbociklibom uz inhibitor aromataze ili fulvestrant iznosi 19 mjeseci (95 % raspon pouzdanosti 9 – 24). Nema značajne razlike u vremenu do progresije s obzirom na to jesu li bolesnice za prvu liniju liječenja metastatske bolesti liječene ribociklibom ili palbociklibom (log-rank test, P = 0,27). Zaključak: Razlika u vremenu do progresije bolesti kod bolesnica s metastatskim hormonski ovisnim rakom dojke liječenih ribociklibom i palbociklibom uz inhibitore aromataze ili fulvestrant nije statistički značajna.
Abstract (english)
Objectives: To examine whether there is a significant difference in progression-free survival in patients with metastatic hormone-positive breast cancer treated with ribociclib and palbociclib plus aromatase inhibitors or fulvestrant Study design: cross-sectional Participants and methods: The study was conducted on 66 patients with metastatic hormone-positive breast cancer treated at the Department of Oncology of the Osijek Clinical Hospital Centre in the period from September 2018 to February 28, 2023. Data on the patients were collected by processing available medical documentation. The study included patients who were treated with ribociclib along with an aromatase inhibitor or fulvestrant in the first line of treatment for metastatic disease and patients who were treated with palbociclib along with an aromatase inhibitor or fulvestrant in the first line of treatment for metastatic disease. Results: In the first-line treatment of metastatic hormone-positive breast cancer, 35 patients were treated with ribociclib, and 31 patients were treated with palbociclib along with aromatase inhibitors or fulvestrant. The median progression-free survival in patients treated with ribociclib with an aromatase inhibitor or fulvestrant was 11 months (95% confidence interval 6-15), and in patients treated with palbociclib with an aromatase inhibitor or fulvestrant was 19 months (95% confidence interval 9-24). There were no significant differences in progression-free survival according to whether patients were treated with ribociclib or palbociclib for first-line treatment of metastatic disease (log-rank test, P = 0.27). Conclusion: The difference in progression-free survival in patients with metastatic hormone-positive breast cancer treated with ribociclib and palbociclib plus aromatase inhibitors or fulvestrant is not statistically significant.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:594692
Study programmeTitle: University Graduate Studies
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-14 10:48:03